Human IgG antibody Laboratories manufactures the antibody curves in sars-1 reagents distributed by Genprice. The Antibody Curves In Sars-1 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Antibody. Other Antibody products are available in stock. Specificity: Antibody Category: Curves Group: In Sars-1
NSP8, His-tag (SARS-CoV-2) |
|||
100830-1 | BPS Bioscience | 100 µg | EUR 335 |
Description: SARS-CoV-2 nonstructural protein 8 (NSP8), Genbank Accession No.: YP 009725304.1, a.a. 1-198(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 23 kDa. |
ORF9b, GST-Tag (SARS-CoV-2) |
|||
100962-1 | BPS Bioscience | 100 µg | EUR 320 |
Description: Recombinant ORF9b, full length, encompassing amino acids 1-97(end). This recombinant protein corresponds to SARS-CoV-2 accessory protein ORF9b. It was expressed in E.coli and contains an N-terminal GST tag and a prescission protease cleavage site. The recombinant protein is >90% pure following GST affinity purification. |
SARS Antibody |
|||
DF15539 | Affbiotech | 100ul | EUR 420 |
SARS antibody |
|||
70R-20086 | Fitzgerald | 50 ul | EUR 522 |
Description: Rabbit polyclonal SARS antibody |
SARS antibody |
|||
70R-1444 | Fitzgerald | 100 ug | EUR 452.4 |
Description: Rabbit polyclonal SARS antibody raised against the C terminal of SARS |
SARS antibody |
|||
70R-1445 | Fitzgerald | 100 ug | EUR 452.4 |
Description: Rabbit polyclonal SARS antibody raised against the middle region of SARS |
SARS antibody |
|||
39139-100ul | SAB | 100ul | EUR 302.4 |
Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
78144-1 | BPS Bioscience | 100 µl | EUR 835 |
Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility._x000D_ |
Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter) |
|||
78159-1 | BPS Bioscience | 100 µl | EUR 835 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with P.1 mutations, see below for details) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility. |
SARS Antibody, HRP conjugated |
|||
1-CSB-PA04145B0Rb | Cusabio |
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
SARS Antibody, FITC conjugated |
|||
1-CSB-PA04145C0Rb | Cusabio |
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
SARS Antibody, Biotin conjugated |
|||
1-CSB-PA04145D0Rb | Cusabio |
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
SARS-CoV-2 Antigen Rapid Test Kit |
|||
CoV2Ag-1 | UnScience | 1T | EUR 9.6 |
Description: This kit adopts the sandwich method and the technical principle of colloidal gold immunochromatography to qualitative determine the SARS-CoV-2 antigen. During the test, the sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 antigen in the sample combined with the colloidal goldlabeled SARS-CoV-2 monoclonal antibody I, and then spread to the test area. It is captured by another coated antibody (SARS-CoV-2 monoclonal antibody II), to form a complex and gather in the test area (T line). The quality control area is coated with the goat antimouse antibody, and the colloidal gold-labeled antibody is captured to form a complex and aggregate in the quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample needs to be tested again. |
3CL Protease (SARS-CoV-2) Assay Kit |
|||
79955-1 | BPS Bioscience | 96 rxns. | EUR 910 |
Description: The 3CL Protease Assay Kit is designed to measure 3CL Protease activity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps. 3CL inhibitor GC376 is also included as an inhibitor control. |
Spike S2, Fc-Tag (SARS-CoV-2) |
|||
100895-1 | BPS Bioscience | 100 µg | EUR 700 |
Description: SARS-CoV-2 Spike protein S2 subunit, also known as 2019-nCoV Spike S2, GenBank Accession No. MN908947, a.a. 686-1212, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=130 kDa. |
Spike S1 Neutralizing Antibody (VHH), Fc-fusion (IgG1), Avi-Tag (SARS-CoV-1), Biotin-labeled |
|||
100785-1 | BPS Bioscience | 50 µg | EUR 355 |
Description: SARS-CoV-1 monoclonal Spike S1 VHH neutralizing antibody, a.a. 1-127(full length), with C-terminal Avi-Tag fused to the Fc portion of Human IgG1, expressed in a HEK293 cell expression system. MW = 43 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%. VHHs are single-domain antibodies from camelids. |
Spike (BQ.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78697-1 | BPS Bioscience | 100 µl | EUR 835 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of October 2022, several new BA.5 sub-lineages (e.g. BQ.1, BQ.1.1, BF.7) have been designated._x000D_The spike protein of BQ.1 omicron variant has additional mutations (K444T and N460K) based on the BA.5 variant. The Spike (BQ.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BQ.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BQ.1, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BQ.1 variant in a Biosafety Level 2 facility._x000D_
|